• ARIAD (ARIA) Phase 2 Results of Iclusig for Myeloid Leukemia

       (0 reviews)

    Biotech_Forecast
    Clinical and Regulatory
    Event Type: Phase 2 Results
    Timing: Q4 2016
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Oncology
    Indication: Myeloid Leukemia
    Lead Indication?: No
    Treatment Name: Iclusig (ponatinib)

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: ARIAD
    Stock Symbol: ARIA
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://investor.ariad.com/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=2078294
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

    Quote

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 10, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the first patient has been treated in its OPTIC (Optimizing PonatinibTreatment In CML) trial of Iclusig® (ponatinib). This randomized, dose-ranging trial is designed to evaluate three starting doses of ponatinib in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML) and is expected to inform the optimal use of Iclusig in these patients. Approximately 450 patients will be enrolled at clinical sites around the world.

     

    Quote

     

    Preliminary data from the OPTIC trial is expected at the end of 2016.


     


      Report Event


    User Feedback

    There are no reviews to display.